Latest Healthcare Sector News

ParagonCare appoints Carmen Riley as CEO effective July 1, 2025, with a planned transition period under outgoing CEO David Collins to complete integration and pursue M&A opportunities.

Microba Life Sciences Limited has had its trading suspension lifted following a capital raising announcement, signaling renewed market activity for the healthcare company.

Arena REIT has declared a quarterly distribution of 4.5625 cents per security, consistent with its FY25 guidance, while offering a 1.5% discount on reinvested dividends through its DRP.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

Monash IVF Group has announced the resignation of CEO Michael Knaap, with CFO Malik Jainudeen stepping in as Acting CEO during the leadership transition.

Austco Healthcare has completed its strategic acquisition of New Zealand’s G&S Technologies, enhancing its healthcare communication offerings and direct sales reach in the region.

Fisher & Paykel Healthcare has announced an ordinary dividend of NZD 0.28235294 per share for the six months ending March 31, 2025, payable on July 4. The dividend is unfranked and includes a supplementary component, with a 15% withholding tax applied.

Epsilon Healthcare has emerged from Administration, securing expanded medicinal cannabis manufacturing permits and launching a new pharmacy brand as part of a strategic turnaround and growth plan.

Wellnex Life Limited’s shares have been suspended from trading on the ASX pending a response to regulatory queries, stirring investor uncertainty.

Atomo Diagnostics has released a Target Market Determination for a new capital raising involving options and shares, including a $1 million Share Purchase Plan and placement offer. The move targets eligible Australian shareholders and aims to bolster the company’s financial position amid a speculative investment environment.

Appen Limited reported robust 2024 results with a 16% revenue increase excluding Google and a return to profitability, driven by generative AI projects and China market expansion. The company outlines a confident 2025 strategy focused on AI data quality, operational efficiency, and sustained growth.

Lumos Diagnostics has secured its largest single US purchase order for its rapid respiratory test FebriDx, signaling growing adoption in American healthcare settings.